Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Dermatology Trial Associates

Neither a doctor nor a teaching hospital

Research payments

$1,761,035

921 payments

Through program year 2025, Dermatology Trial Associates is reported as receiving $1,761,035 in research payments, across 921 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $544,589 65
2024 Research $261,368 452
2023 Research $181,904 243
2022 Research $108,579 55
2021 Research $102,808 22
2020 Research $448,474 56
2019 Research $113,313 28

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $451,169 92 payments
  2. AbbVie, Inc. $384,029 57 payments
  3. VYNE Pharmaceuticals Inc. $200,290 23 payments
  4. Dermavant Sciences, Inc. $177,401 650 payments
  5. Eli Lilly and Company $156,676 2 payments
  6. Arcutis Biotherapeutics, Inc. $91,471 26 payments
  7. Bausch Health US, LLC $78,772 7 payments
  8. Taro Pharmaceuticals USA, Inc. $64,860 24 payments
  9. Sanofi US Services Inc. $54,671 14 payments
  10. Amgen Inc. $42,425 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3B4 Multicenter Randomized Assessor Blinded Vehicle and Active Topical Corticosteroid and Calcineurin Inhibitor Controlled Parallel Group Study of the Efficacy Safety and Local Tolerability of Crisaborole Ointment 2 in Pediatric and Adult Subjects Ages 2 Years and Older With Mild to Moderate Atopic Dermatitis $226,854 38 payments
  2. Fx2016-40 $200,290 23 payments
  3. A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $182,951 42 payments
  4. A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa $167,462 10 payments
  5. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study of Ly4100511 (Dc-853) for the Treatment of Adult Participants With Moderate-To Severe Plaque Psoriasis $156,676 2 payments
  6. M18-891 $73,084 7 payments
  7. An Open Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis $69,467 78 payments
  8. A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study to Compare the Safety and Efficacy of Idp-126 Gel to Epiduo? Forte Gel (0.3% Adapalene/2.5% Bpo), in the Treatment of Acne Vulgaris $68,857 5 payments
  9. An Open Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis $66,191 411 payments
  10. A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis $53,513 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record